- YOU ARE HERE: (Aidsmap)
In a series of oral presentations at the XVII International AIDS Conference last week, investigators presented data from several trials on whether continuous use of aciclovir to suppress HSV-2 infection could curb HIV transmission.
- BioAlliance Pharma appoints Pierre MORGON Chief Operating Officer and Member of the Management Board (wallstreet:online AG)
Regulatory News: BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused
- A papilloma of a virus? (The Star)
Though much has been said about the human papilloma virus as one of the main culprits in cervical cancer, let?s not forget that these group of viruses cause other problems, too.
- Genital herpes treatment does not prevent HIV (Reuters via Yahoo! News)
Long-term treatment of genital herpes with the drug acyclovir does not reduce the rate of new HIV infections, researchers reported at the International AIDS Conference here last week.
- BioAlliance Pharma Publishes Its Consolidated Half-Year Accounts to June 30, 2008: Increased Revenue and Reinforced ... (Business Wire via Yahoo! Finance)
PARIS----Regulatory News:
- BioAlliance Pharma SA appoints Pierre MORGON Chief Operating Officer (Marketwire via Yahoo! Finance)
BioAlliance Pharma SA, the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it has strengthened its Management Board with the appointment of Pierre MORGON as Chief Operating Officer (COO).
- BioAlliance Pharma SA publishes its consolidated half-year accounts to June 30, 2008 (Marketwire via Yahoo! Finance)
BioAlliance Pharma publishes its consolidated half- year accounts to June 30, 2008: increased revenue and reinforced growth via new licensing agreements
- BioAlliance Pharma SA announces the grant of its main patent on the Lauriad(R) technology in Europe (Marketwire via Yahoo! Finance)
BioAlliance Pharma announces the grant of its main patent on the Lauriad® technology in Europe